Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan M. Bartolucci Sells 818 Shares

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan M. Bartolucci sold 818 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $81.87, for a total transaction of $66,969.66. Following the completion of the sale, the chief accounting officer now owns 46,182 shares in the company, valued at $3,780,920.34. This represents a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Tempus AI Stock Performance

Shares of TEM traded down $8.99 during mid-day trading on Thursday, hitting $76.72. 20,409,815 shares of the company’s stock were exchanged, compared to its average volume of 14,385,644. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45. The company has a 50-day simple moving average of $49.75 and a 200 day simple moving average of $51.44. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently made changes to their positions in the company. Operose Advisors LLC bought a new position in shares of Tempus AI in the fourth quarter valued at $25,000. First Horizon Advisors Inc. bought a new position in shares of Tempus AI in the third quarter valued at $30,000. Farther Finance Advisors LLC bought a new position in shares of Tempus AI in the fourth quarter valued at $34,000. Prestige Wealth Management Group LLC grew its stake in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after buying an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new position in shares of Tempus AI in the fourth quarter valued at $49,000. 24.22% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research report on Tuesday, January 14th. TD Cowen restated a “buy” rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and raised their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Bank of America raised their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Finally, Piper Sandler restated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Tempus AI presently has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.